Agios Pharmaceuticals (AGIO) Accumulated Depreciation & Amortization (2016 - 2024)
Historic Accumulated Depreciation & Amortization for Agios Pharmaceuticals (AGIO) over the last 13 years, with Q4 2024 value amounting to $56.5 million.
- Agios Pharmaceuticals' Accumulated Depreciation & Amortization rose 817.17% to $56.5 million in Q4 2024 from the same period last year, while for Dec 2024 it was $56.5 million, marking a year-over-year increase of 817.17%. This contributed to the annual value of $56.5 million for FY2024, which is 817.17% up from last year.
- Agios Pharmaceuticals' Accumulated Depreciation & Amortization amounted to $56.5 million in Q4 2024, which was up 817.17% from $52.2 million recorded in Q4 2023.
- Over the past 5 years, Agios Pharmaceuticals' Accumulated Depreciation & Amortization peaked at $56.5 million during Q4 2024, and registered a low of $41.4 million during Q4 2020.
- In the last 5 years, Agios Pharmaceuticals' Accumulated Depreciation & Amortization had a median value of $50.1 million in 2022 and averaged $49.0 million.
- Its Accumulated Depreciation & Amortization has fluctuated over the past 5 years, first soared by 41135.16% in 2020, then soared by 431.2% in 2023.
- Agios Pharmaceuticals' Accumulated Depreciation & Amortization (Quarter) stood at $41.4 million in 2020, then increased by 8.76% to $45.0 million in 2021, then grew by 11.33% to $50.1 million in 2022, then rose by 4.31% to $52.2 million in 2023, then increased by 8.17% to $56.5 million in 2024.
- Its Accumulated Depreciation & Amortization stands at $56.5 million for Q4 2024, versus $52.2 million for Q4 2023 and $50.1 million for Q4 2022.